The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian chronic hepatitis B patients: friend or foe?

Abstract

We read with great interest the article by Liu et al.¹ They found that hepatitis B surface antigen (HBsAg level) < 100 IU/mL at end‐of‐treatment (EOT) seemed to be a useful marker to decide when to stop NAs therapy because it was associated with a low incidence (20‐30%) of virological or clinical relapse and high probability (20‐60%) of HBsAg loss for chronic hepatitis B (CHB) patients. Although this systemic review provided a practical and attainable cessation criterion instead of infinite NAs treatment, several issues deserve discussion and further investigations.

This article is protected by copyright. All rights reserved.

http://bit.ly/2BeQF0O